Albina Nowak, MD
Albina Nowak, MD
The goal of this clinical trial is to test dapagliflizone in Fabry patients. The main questions it aims to answer are: Has 10 mg/d of dapagliflozin a positive effect on kidney functions of Fabry patients. Has 10 mg/d of dapagliflozin a positive effect on heart functions in Fabry patients. Participants will be asked to Sign an informed consent Give a blood and urine samples Be subjected to Echocardiography investigation Take 10 mg/day Dapagliflizone Researchers will compare treatment to placebo groups to see if kidneys and heart functions will be improved in the treatment group better more than the placebo group.
Fabry Disease
Dapagliflozin 10mg Tab
Placebo
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 46 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients; A Prospective, Randomized, Double-Blind, Placebo- Controlled Study. |
Actual Study Start Date : | August 2023 |
Estimated Primary Completion Date : | August 2024 |
Estimated Study Completion Date : | August 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Dapagliflozin 10mg Tab SGLT2is- Dapagliflozin (Forxiga): 10 mg/d, oral drug |
Drug: Dapagliflozin 10mg Tab |
Placebo Comparator: Placebo Placebo tablet will have the same color, taste, smell and package as the verum tablet |
Drug: Placebo |
Ages Eligible for Study: | 18 Years to 70 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.